Background/Aims: In end-stage renal disease (ESRD), hyperhomocysteinemia is a common finding associated with increased cardiovascular risk. However, the pathogenic role of homocysteine is still unclear. In vitro studies show that thiol redox status affects endothelial cell functions. We therefore investigated the possible association between homocysteinemia and plasma thiol redox status in ESRD patients. Methods: Total plasma homocysteine (Hcy), cysteine (Cys) and free thiols (SH) were measured both before and after a dialytic session in 54 ESRD patients receiving (n = 15) or not receiving (n = 39) folate supplementation, and 17 control subjects. Results: High predialysis levels of both Hcy and Cys were found to be negatively correlated with low SH levels both in supplemented (r = –0.680, p < 0.01 and r = –0.624, p < 0.02, respectively) and unsupplemented (r = –0.698, p < 0.001 and r = –0.445, p < 0.01, respectively) patients. Following dialysis, SH values returned to normal and the above correlations were no longer appreciable. Conclusion: A strong, folate therapy-insensitive association between homocysteinemia and plasma free thiol levels was found in ESRD patients. These results support a role for oxidative stress in ESRD-related hyperhomocysteinemia and suggest the plasma thiol redox status alteration as a possible pathogenic mechanism underlying the cardiovascular toxicity of hyperhomocysteinemia in these patients.

Keywords:
Homocysteine, Oxidative stress, End-stage renal disease, Cardiovascular disease, Dialysis, Sulfhydryl compounds
1.
Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GH, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales Luis AC, Parrot-Rouland FM, Tan KS, Higgins I, Garcon D, Andria G: Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277:1775–1781.
2.
Zoccali C: Traditional and emerging cardiovascular and renal risk factors: an epidemiologic perspective. Kidney Int 2006;70:26–33.
3.
Grekas D, Economou H, Makedou A, Destanis E, Theodoridou A, Avdelidou A, Demitriadis A, Tourkantonis A: Association between hyperhomocysteinemia and ultrasonographic atherosclerotic indices of carotid arteries in chronic hemodialysis patients. Nephron Clin Pract 2005;101:c180-c186.
4.
Perna AF, Satta E, Acanfora F, Lombardi C, Ingrosso D, De Santo NG: Increased plasma protein homocysteinylation in hemodialysis patients. Kidney Int 2006;69:869–876.
5.
Andersson A, Lindgren A, Arnadottir M, Prytz H, Hultberg B: Thiols as a measure of plasma redox status in healthy subjects and in patients with renal or liver failure. Clin Chem 1999;45:1084–1086.
6.
van GC, Kulik W, Berger R, Dijkstra DA, Jakobs C, Reijngoud DJ, Donker AJ, Stehouwer CD, De MK: Homocysteine and methionine metabolism in ESRD: a stable isotope study. Kidney Int 1999;56:1064–1071.
7.
Stam F, van GC, Ter Wee PM, Jakobs C, De MK, Stehouwer CD: Effect of folic acid on methionine and homocysteine metabolism in end-stage renal disease. Kidney Int 2005;67:259–264.
8.
Ingrosso D, Cimmino A, Perna AF, Masella L, De Santo NG, De Bonis ML, Vacca M, D’Esposito M, D’Urso M, Galletti P, Zappia V: Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet 2003;361:1693–1699.
9.
Mansoor MA, Svardal AM, Ueland PM: Determination of the in vivo redox status of cysteine, cysteinylglycine, homocysteine, and glutathione in human plasma. Anal Biochem 1992;200:218–229.
10.
Suliman M, Anderstam B, Lindholm B, Bergstrom J: Total, free, and protein-bound sulphur amino acids in uraemic patients. Nephrol Dial Transplant 1997;12:2332–2338.
11.
Himmelfarb J, McMenamin E, McMonagle E: Plasma aminothiol oxidation in chronic hemodialysis patients. Kidney Int 2002;61:705–716.
12.
Teschner M, Kosch M, Schaefer RM: Folate metabolism in renal failure. Nephrol Dial Transplant 2002;17(suppl 5):24–27.
13.
Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP: Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004;15:420–426.
14.
Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M: Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565–575.
15.
Suliman ME, Stenvinkel P, Lindholm B: Is hyperhomocysteinemia a contributor to atherosclerosis in chronic kidney disease patients? Nephron Clin Pract 2005;101:c187–c189.
16.
Andersson A, Jonasson T, Ohlin H, Lindgren A, Hultberg B: Vitamin supplementation normalizes total plasma homocysteine concentration but not plasma homocysteine redox status in patients with acute coronary syndromes and hyperhomocysteinemia. Clin Chem Lab Med 2002;40:554–558.
17.
Deneke SM: Thiol-based antioxidants. Curr Top Cell Regul 2000;36:151–180.
18.
Usatyuk PV, Parinandi NL, Natarajan V: Redox regulation of 4-hydroxy-2-nonenal-mediated endothelial barrier dysfunction by focal adhesion, adherens, and tight junction proteins. J Biol Chem 2006;281:35554–35566.
19.
Himmelfarb J, McMonagle E, McMenamin E: Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int 2000;58:2571–2578.
20.
Gerardi G, Usberti M, Martini G, Albertini A, Sugherini L, Pompella A, Di LD: Plasma total antioxidant capacity in hemodialyzed patients and its relationships to other biomarkers of oxidative stress and lipid peroxidation. Clin Chem Lab Med 2002;40:104–110.
21.
Galli F, Floridi AG, Floridi A, Buoncristiani U: Accumulation of vitamin E metabolites in the blood of renal failure patients. Clin Nutr 2004;23:205–212.
22.
Giri S, Thompson PD, Taxel P, Contois JH, Otvos J, Allen R, Ens G, Wu AH, Waters DD: Oral estrogen improves serum lipids, homocysteine and fibrinolysis in elderly men. Atherosclerosis 1998;137:359–366.
23.
Ubbink JB, van der MA, Delport R, Allen RH, Stabler SP, Riezler R, Vermaak WJ: The effect of a subnormal vitamin B-6 status on homocysteine metabolism. J Clin Invest 1996;98:177–184.
24.
Vilaseca MA, Monros E, Artuch R, Colome C, Farre C, Valls C, Cardo E, Pineda M: Anti-epileptic drug treatment in children: hyperhomocysteinaemia, B-vitamins and the 677C–>T mutation of the methylenetetrahydrofolate reductase gene. Eur J Paediatr Neurol 2000;4:269–277.
25.
Daugirdas JT: Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 1993;4:1205–1213.
26.
Pfeiffer CM, Huff DL, Gunter EW: Rapid and accurate HPLC assay for plasma total homocysteine and cysteine in a clinical laboratory setting. Clin Chem 1999;45:290–292.
27.
Sengupta S, Chen H, Togawa T, DiBello PM, Majors AK, Budy B, Ketterer ME, Jacobsen DW: Albumin thiolate anion is an intermediate in the formation of albumin-S-S-homocysteine. J Biol Chem 2001;276:30111–30117.
28.
Hultberg B: Modulation of extracellular homocysteine concentration in human cell lines. Clin Chim Acta 2003;330:151–159.
29.
Sjoberg B, Anderstam B, Suliman M, Alvestrand A: Plasma reduced homocysteine and other aminothiol concentrations in patients with CKD. Am J Kidney Dis 2006;47:60–71.
30.
Hayes D, Wiessner M, Rauen T, McBean GJ: Transport of L-[14C]cystine and L-[14C]cysteine by subtypes of high affinity glutamate transporters over-expressed in HEK cells. Neurochem Int 2005;46:585–594.
31.
Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, Nguyen AT, Thevenin M, Jaudon MC, Zingraff J, Verger C, Jungers P, Descamps-Latscha B: Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med 1996;21:845–853.
32.
Scholze A, Rinder C, Beige J, Riezler R, Zidek W, Tepel M: Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation 2004;109:369–374.
33.
Friedman AN, Bostom AG, Laliberty P, Selhub J, Shemin D: The effect of N-acetylcysteine on plasma total homocysteine levels in hemodialysis: a randomized, controlled study. Am J Kidney Dis 2003;41:442–446.
34.
Tepel M, van der GM, Statz M, Jankowski J, Zidek W: The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003;107:992–995.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.